Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 9/20 | 0.38 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.38 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.38 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6891056 | 0.90 | TSPO (0.42) | PTGDR2 | |
| SCHEMBL6773208 | 0.90 | CTNNB1 (0.42) | CTNNB1BRD4PLA2G2APLA2G1BPLA2G10 | |
| SCHEMBL6776025 | 0.89 | CTNNB1 (0.43) | CTNNB1BRD4PLA2G2APLA2G1BPLA2G10 | |
| SCHEMBL6774146 | 0.89 | CTNNB1 (0.49) | CTNNB1PLA2G2APLA2G1BPLA2G10PLA2G5 | |
| SCHEMBL6772343 | 0.88 | CTNNB1 (0.40) | CTNNB1BRD4PLA2G2APLA2G1BPLA2G10 | |
| SCHEMBL7966138 | 0.87 | PLA2G2A (0.49) | PLA2G2APLA2G1BPLA2G10PLA2G5 | |
| SCHEMBL6772666 | 0.86 | CTNNB1 (0.41) | CTNNB1PLA2G2A | |
| SCHEMBL6776978 | 0.85 | PLA2G2A (0.42) | PLA2G2APLA2G1BPLA2G10PLA2G5SIRT2 | |
| SCHEMBL6775835 | 0.85 | CCR8 (0.41) | CTNNB1BRD4PLA2G2APLA2G1BPTGDR2 | |
| SCHEMBL6773425 | 0.85 | PLA2G2A (0.42) | PLA2G2ASIRT2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713645-B1 | INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK | ELI LILLY AND COMPANY | 2004-03-30 | — | — | US | disclosed |
| US-6177440-B1 | THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR | ELI LILLY AND COMPANY | 2001-01-23 | — | — | US | disclosed |
| EP-0952149-A2 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | ELI LILLY AND COMPANY (US) | 1999-10-27 | — | — | EP | disclosed |